Below is a featured video from the September 2023 case conference, during which Tuya Pal, MD, FACMG from Vanderbilt University Medical Center presents on recent updated to the National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic cancer guidelines. Please visit our YouTube channel to watch the full September conference, including valuable discussion about …
Tag: Screening/Early Detection
Permanent link to this article: https://inheritedcancer.net/video91423/
ICARE Social Media Post August 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
ICARE Social Media Post August 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on August 28th, 2023, which included: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Permanent link to this article: https://inheritedcancer.net/post82923/
ICARE Social Media Post July 2023
CDKN2A Mutations: Pancreatic Cancer Screening over 20 years of follow up
ICARE Social Media Post July 2023
CDKN2A Mutations: Pancreatic Cancer Screening over 20 years of follow up
A study among CDKN2A carriers assessing the yield and outcomes of 20 years of pancreatic cancer screening found: These results highlight the potential importance of pancreatic cancer screening among CDKN2A carriers. Currently, NCCN guidelines recommend annual pancreatic cancer screening starting at age 40, regardless of family history. Use the link in bio to learn more! …
Permanent link to this article: https://inheritedcancer.net/post70223/
ICARE Social Media Post June 2023
Breast Cancer Risk Model: Predicting Risk over 10-year period
ICARE Social Media Post June 2023
Breast Cancer Risk Model: Predicting Risk over 10-year period
A new study found that mammographic features (density, microcalcifications, masses, and left-right breast asymmetries) predicted risks better than traditional lifestyle/familial risk-based risk models over a 10-year period. Use the link in our bio to learn more! Reference: Eriksson et al. J Clin Oncol. 2023;JCO2201564. PMID: 36930854.
Permanent link to this article: https://inheritedcancer.net/post62823/
ICARE Social Media Post June 2023
Should Black women be screened earlier?
ICARE Social Media Post June 2023
Should Black women be screened earlier?
A recent study found that Black women had the highest rate of breast cancer deaths in their 40s, compared to White women and women of other races and ethnicities. Read the full article at the link in our bio to learn more! Reference: Chen T, et al. JAMA Netw Open. 2023;6(4):e238893. PMID: 37074714.
Permanent link to this article: https://inheritedcancer.net/post62023/
Permanent link to this article: https://inheritedcancer.net/post62223/
ICARE Social Media Post June 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Colorectal Version 1.2023
ICARE Social Media Post June 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Colorectal Version 1.2023
The National Comprehensive Cancer Network (NCCN) just released updated colorectal cancer guidelines which includes: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
Permanent link to this article: https://inheritedcancer.net/post60823/
ICARE Social Media Post May 2023
Women’s Health Week
ICARE Social Media Post May 2023
Women’s Health Week
In honor of National Women’s Health Week from May 14th to May 20th, we would like to encourage you to speak with your healthcare provider to make sure you are up-to-date on your cancer screenings, such as mammograms and colonoscopies, to help prevent cancer or find it early when it is easier to treat. Spread …
Permanent link to this article: https://inheritedcancer.net/post51523/
ICARE Social Media Post May 2023
USPSTF New Recommendation: Mammograms Start at Age 40
ICARE Social Media Post May 2023
USPSTF New Recommendation: Mammograms Start at Age 40
Yesterday the United States Preventive Services Task Force (USPSTF) published a new draft recommendation for all cisgender women and those assigned female sex at birth to do mammograms from ages 40 to 74, every two years. This change in recommendation is due to recent troubling trends, including an increase in the number of cancers diagnosed …
Permanent link to this article: https://inheritedcancer.net/post51023/
ICARE Newsletter Spring 2023
Community Spotlight
ICARE Newsletter Spring 2023
Community Spotlight
In 1997 when I was a junior in college, my mom called to let me know that my father had been diagnosed with prostate cancer. Luckily for him, Prostate Specific Antigen (PSA) testing had recently started which resulted in early detection and subsequent prostatectomy. Due to his diagnosis and knowing prostate cancer is an inherited …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023span-stylecolor-56b0e4community-spotlight/
ICARE Newsletter Spring 2023
Ask the Expert
ICARE Newsletter Spring 2023
Ask the Expert
The below question was addressed by Ben Ho Park, MD, PhD, who is the Director of the Vanderbilt-Ingram Cancer Center and a Professor of Medicine in the Division of Hematology and Oncology. If you have a question you would like addressed, please email the ICARE team at ICARE@vumc.org for consideration in future newsletters. Q: As …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023ask-the-expert/
ICARE Newsletter Spring 2023
Breast Cancer Screening in Male BRCA1/2 Carriers
ICARE Newsletter Spring 2023
Generally, males with breast cancer present with advanced stage disease, thought to be due to a lack of screening. While data to determine performance of breast screening through mammograms for males at inherited risk is limited, recent studies suggest that the detection rate is similar or better than for females at general population risk.1,2,3 In …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-breast-cancer-screening-in-male-brca1-2-carriers/
ICARE Newsletter Spring 2023
Inherited Breast Cancer: Contralateral Breast Cancer Risks
ICARE Newsletter Spring 2023
Inherited Breast Cancer: Contralateral Breast Cancer Risks
While higher risks for contralateral breast cancer (CBC) have been known for BRCA1 and BRCA2, a newly published study demonstrated that the risk of CBC is also higher for female PALB2 and CHEK2 carriers; however, no elevated risks were found for ATM carriers (Table 1).1 This information is important to study, as it may be …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-inherited-breast-cancer-contralateral-breast-cancer-risks/
ICARE Social Media Post March 2023
New Model: To identify those at high risk for Endometrial (Uterine) Cancer
ICARE Social Media Post March 2023
New Model: To identify those at high risk for Endometrial (Uterine) Cancer
Did you know endometrial cancer is the 4th most common cancer among females? Currently, clinical practice guidelines do not recommend endometrial cancer screening in the general population. A new risk prediction model was recently developed to identify those at high risk for endometrial (uterine) cancer to determine who could benefit from cancer screenings and risk-reducing …
Permanent link to this article: https://inheritedcancer.net/post32623/
ICARE Social Media Post February 2023
ATM Gene and Breast Cancer Risk for: c.7570G>C Mutation
ICARE Social Media Post February 2023
ATM Gene and Breast Cancer Risk for: c.7570G>C Mutation
While ATM mutations are generally associated with a 25-30% lifetime risk for breast cancer, emerging information suggests that the risk in those with a c.7570G>C mutation may be higher. Once confirmed, this information may be important to guide cancer screening and risk-reducing surgery decisions. Use the link in our bio to learn more!
Permanent link to this article: https://inheritedcancer.net/post40623/
ICARE Newsletter Spring 2022
Reducing Hereditary Cancer Act of 2021
ICARE Newsletter Spring 2022
Reducing Hereditary Cancer Act of 2021
On February 16th, 2022, the Reducing Hereditary Cancer Act (S.3656) was introduced to the U.S. Senate with the goal of ensuring Medicare beneficiaries have coverage for potentially life-saving inherited cancer genetic counseling and testing as well as recommended screening and risk-reducing procedures, when medically necessary and appropriate. Currently, Medicare only covers genetic testing for beneficiaries …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-reducing-hereditary-cancer-act-of-2021/
ICARE Newsletter Spring 2022
Community Spotlight
ICARE Newsletter Spring 2022
Community Spotlight
Genetic testing sounded like a futuristic concept when it originally came to our attention. It sounded something to the likes of cloning. We didn’t really understand what it was and why it was important, but rather thought it sounded like something out of science fiction. Thankfully, our medical providers and genetic counselors stuck with us …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-community-spotlight/
ICARE Newsletter Spring 2022
Lynch Syndrome and Prostate Cancer
ICARE Newsletter Spring 2022
Lynch Syndrome and Prostate Cancer
A new study suggests men with certain MSH2 and MSH6 mutations have higher risks of prostate cancer and may be candidates for PSA screening. Bancroft et al. Lancet Oncol. 2021 Nov. PMID: 34678156. Social media postDecember 17th, 2021. Available at: https://tinyurl.com/post121721
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-lynch-syndrome-and-prostate-cancer/
ICARE Newsletter Spring 2022
Polygenic Risk Scores and Inherited Breast Cancer Genes: BRCA1/2, PALB2, CHEK2, and ATM
ICARE Newsletter Spring 2022
Polygenic Risk Scores and Inherited Breast Cancer Genes: BRCA1/2, PALB2, CHEK2, and ATM
Breast MRIs are advised in women with >20% lifetime risk of breast cancer. A new study showed that breast cancer risks in BRCA1, BRCA2 and PALB2 carriers remained higher than 20%, regardless of whether polygenic risk scores (PRS) were done, suggesting this is of limited help in refining screening. In contrast, PRS downgraded breast cancer …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-polygenic-risk-scores-and-inherited-breast-cancer-genes-brca1-2-palb2-chek2-and-atm/
ICARE Newsletter Fall 2022
Community Spotlight
ICARE Newsletter Fall 2022
Community Spotlight
When I was just 8 years old my mother was diagnosed with a very aggressive breast cancer. I didn’t reallyunderstand the concept of cancer at that age, but I knew what was happening was terrible. After manysurgeries and treatments, she passed away 2 years later at the age of 35. There was no hereditary cancertesting …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-community-spotlight/
ICARE Newsletter Fall 2022
Ask the Expert
ICARE Newsletter Fall 2022
Ask the Expert
The below question was addressed by Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro Intestinal Surgical Oncology at Vanderbilt-Ingram Cancer Center. Dr. Idrees’ research has focused on colorectal cancer, liver metastases, and pancreatic cancer …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-ask-the-expert/
ICARE Newsletter Fall 2022
Screening & Treatment Updates: New Modeling Analysis About Breast Cancer Screening in ATM and CHEK2 Carriers
ICARE Newsletter Fall 2022
Screening & Treatment Updates: New Modeling Analysis About Breast Cancer Screening in ATM and CHEK2 Carriers
Using information from twelve prior population-based studies, a modeling analysis was done to look at when to start mammography and breast MRI in females with inherited mutations in genes including ATM and CHEK2. Overall, findings showed that starting annual MRI screening between age 30 to 35 and mammography at age 40 may lower death from …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-screening-treatment-updates-new-modeling-analysis-about-breast-cancer-screening-in-atm-and-chek2-carriers/
ICARE Newsletter Fall 2022
National Comprehensive Cancer Network (NCCN) Guidelines Updates
ICARE Newsletter Fall 2022
National Comprehensive Cancer Network (NCCN) Guidelines Updates
Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic – Released September 7th, 2022› Testing eligibility based on personal history of any type of breast cancer in females was updated from age ≤45 to ≤50 making more females with breast cancer eligible for testing …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-national-comprehensive-cancer-network-nccn-guidelines-updates/
ICARE Newsletter Fall 2021
Reducing Hereditary Cancer Act of 2021
ICARE Newsletter Fall 2021
Reducing Hereditary Cancer Act of 2021
Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Thus, genetic testing is only covered for those already diagnosed with cancer, regardless of family history. If someone without cancer has an inherited mutation that increases cancer risk (e.g., BRCA1/2), Medicare may not …
Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6icare-newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-reducing-heredit/
ICARE Social Media Post February 2023
Risk for second breast cancer in premenopausal female BRCA1, BRCA2, PALB2 and CHEK2 carriers
ICARE Social Media Post February 2023
Risk for second breast cancer in premenopausal female BRCA1, BRCA2, PALB2 and CHEK2 carriers
Did you know female BRCA1, BRCA2, CHEK2, or PALB2 carriers have much higher risks for contralateral breast cancer?This information is important to guide cancer screening and risk reduction strategies. Use the link in bio to learn more!
Permanent link to this article: https://inheritedcancer.net/post40123/
Newsletter Fall 2021
PALB2 : Increasingly Recognized as the Third Most Important Inherited Breast Cancer Gene
Newsletter Fall 2021
PALB2 : Increasingly Recognized as the Third Most Important Inherited Breast Cancer Gene
In May 2021, a clinical practice resource was released by the American College of Medical Genetics and Genomics (ACMG) from a global team of cancer genetics specialists (see figure) to help guide the care of PALB2 carriers.1 PALB2 is considered the third most important breast cancer risk gene, after BRCA1 and BRCA2, with PALB2 carriers …
Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-ipalb2-i-increas/
ICARE Social Media Post January 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
ICARE Social Media Post January 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
The National Comprehensive Cancer Network (NCCN) just released updated breast, ovarian, and pancreatic cancer guidelines which included updated breast cancer screening recommendations for male BRCA carriers (particularly male BRCA2 carriers). It is now recommended that male BRCA carriers consider annual mammograms starting at age 50 or 10 years before the earliest male breast cancer in …
Permanent link to this article: https://inheritedcancer.net/post12423/
ICARE Social Media Post December 2022
Cancer Screen Week
ICARE Social Media Post December 2022
Cancer Screen Week
This week is Cancer Screen Week! This week we would like to highlight the importance of screening for inherited cancer to help prevent cancer and find it early. Talk to your healthcare provider today about what screenings are best for you.
Permanent link to this article: https://inheritedcancer.net/post120622/
ICARE Social Media Post November 2022
Fall 2022 Ask the Expert
ICARE Social Media Post November 2022
Fall 2022 Ask the Expert
In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro-Intestinal Surgical …
Permanent link to this article: https://inheritedcancer.net/post111122/
ICARE Featured Video October 2022
NCCN Genetic/Familial Guideline Updates (V1.2023 & V.1.2022)
ICARE Featured Video October 2022
NCCN Genetic/Familial Guideline Updates (V1.2023 & V.1.2022)
Below you may watch a featured video from the October 2022 Genetics Case Conference in which ICARE Principal Investigator, Tuya Pal, MD, discusses recent updates to the National Comprehensive Cancer Network (NCCN) guidelines.
Permanent link to this article: https://inheritedcancer.net/video100622/
ICARE Social Media Post October 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 2
ICARE Social Media Post October 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 2
On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, the age to start breast MRI screening in female ATM and CHEK2 carriers was updated from age 40 to 30-35 making more females eligible for screening at an earlier age.Check out the new …
Permanent link to this article: https://inheritedcancer.net/post100222/
ICARE Featured Video August 2022
Total Body MRI Screening Protocol in Li-Fraumeni Syndrome Patients
ICARE Featured Video August 2022
Total Body MRI Screening Protocol in Li-Fraumeni Syndrome Patients
Below you may watch a featured video from the August 2022 Genetics Case Conference focused on total body MRI screening protocol in Li-Fraumeni Syndrome patients with guest expert Joanna Shechtel, MD.
Permanent link to this article: https://inheritedcancer.net/video81122/
ICARE Social Media Post July 2022
Pancreatic Cancer Screening
ICARE Social Media Post July 2022
Pancreatic Cancer Screening
A recent study found that earlier diagnosis improved survival in people at high risk of pancreatic cancer.High risk was defined based on:family history and/orinherited gene mutation (BRCA1, BRCA2, CDKN2A, Lynch Syndrome genes, PALB2, ATM, and STK11)Read the article at the link in our bio! 🔗Reference: Dbouk, et al. J Clin Oncol. 2022 Jun 15:JCO2200298. doi: …
Permanent link to this article: https://inheritedcancer.net/post72622/
ICARE Social Media Post June 2022
Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results
ICARE Social Media Post June 2022
Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results
A new study found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a small proportion of pregnant women. However, among those with suspicious findings, the risk of a confirmed malignancy was quite high.Check out the full article athttps://ascopubs.org/doi/full/10.1200/JCO.21.02260Reference: Heesterbeek et …
Permanent link to this article: https://inheritedcancer.net/post60822/
Permanent link to this article: https://inheritedcancer.net/post40522/
ICARE Social Media Post April 2022
Breast Cancer Mortality & MRI Screening: ATM, CHEK2, and PALB2
ICARE Social Media Post April 2022
Breast Cancer Mortality & MRI Screening: ATM, CHEK2, and PALB2
A new study suggests that annual breast MRI screening may reduce deaths from breast cancer by half in women with ATM, CHEK2 and PALB2 gene mutations. The data suggests starting with annual breast MRIs between the ages of 30 to 35, and adding annual mammograms starting at age 40. Read the full article to learn …
Permanent link to this article: https://inheritedcancer.net/post40122/
ICARE Featured Video January 2022
JScreen: At-Home Genetic Testing and Education
ICARE Featured Video January 2022
JScreen: At-Home Genetic Testing and Education
Below you may watch a featured video from the January 2022 Genetics Case Conference, in which Estie Rose, MS, LCGC presented on JScreen, a non-profit offering genetic testing and education.
Permanent link to this article: https://inheritedcancer.net/video11322/
ICARE Social Media Post December 2021
Prostate Cancer Screening: MSH2 & MSH6
ICARE Social Media Post December 2021
Prostate Cancer Screening: MSH2 & MSH6
A new study suggests men with MSH2 and MSH6 mutations have a higher incidence of prostate cancer, and may be candidates for PSA screening. Read the full article to learn more 👇 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00522-2/fulltext Reference: Bancroft et al. Lancet Oncol. 2021 Nov;22(11):1618-1631. PMID: 34678156.
Permanent link to this article: https://inheritedcancer.net/post121721/
ICARE Social Media Post August 2021
Breast Cancer Risks: BRCA1/2 & PALB2
ICARE Social Media Post August 2021
Breast Cancer Risks: BRCA1/2 & PALB2
For more information, view the article at 👇https://ascopubs.org/doi/full/10.1200/JCO.21.00531
Permanent link to this article: https://inheritedcancer.net/post82421/
ICARE Featured Video August 2021
Updates to National Comprehensive Cancer Network (NCCN) Guidelines
ICARE Featured Video August 2021
Updates to National Comprehensive Cancer Network (NCCN) Guidelines
Below you may watch a featured video from the August 2021 ICARE Genetics Case Conferences outlining updates to National Comprehensive Cancer Network (NCCN) guidelines.
Permanent link to this article: https://inheritedcancer.net/video81221_2/
ICARE Social Media Post June 2021
BRCA: Better Survival with Screening
ICARE Social Media Post June 2021
BRCA: Better Survival with Screening
For more information, please visit: https://www.cancertherapyadvisor.com/home/news/conference-coverage/st-gallen-international-breast-cancer-conference/sg-bcc-2021/breast-cancer-screening-brca-improves-survival-mutation
Permanent link to this article: https://inheritedcancer.net/post62921/
ICARE Social Media Post May 2021
Breast Cancer Awareness Medical Minute
ICARE Social Media Post May 2021
Breast Cancer Awareness Medical Minute
In recognition of 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗠𝗼𝗻𝘁𝗵, listen to our colleague, Dr. Sonya Reid, talk about the importance of mammography for the early detection of breast cancer! To learn more, check out the American Cancer Society’s Recommendations for the Early Detection of Breast Cancer at: https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
Permanent link to this article: https://inheritedcancer.net/post52421/
ICARE Social Media Post May 2021
USPSTF Earlier Colorectal Cancer Screening At Age 45
ICARE Social Media Post May 2021
USPSTF Earlier Colorectal Cancer Screening At Age 45
The United States Preventive Services Task Force (USPSTF) now recommends routine colorectal cancer screening begin at age 45 (lowered from the previous recommendation to start screening at age 50) due to an increasing number of colorectal cancer cases in younger adults. For more information, check out the full JAMA article at: https://jamanetwork.com/journals/jama/fullarticle/2779985
Permanent link to this article: https://inheritedcancer.net/post52121/
ICARE Social Media Post May 2021
CDKN2A: Cancer Risks and Risk Management
ICARE Social Media Post May 2021
CDKN2A: Cancer Risks and Risk Management
𝘐𝘯 𝘳𝘦𝘤𝘰𝘨𝘯𝘪𝘵𝘪𝘰𝘯 𝘰𝘧 𝘴𝘬𝘪𝘯 𝘤𝘢𝘯𝘤𝘦𝘳 𝘢𝘸𝘢𝘳𝘦𝘯𝘦𝘴𝘴 𝘮𝘰𝘯𝘵𝘩, we present cancer risks and management for 𝗖𝗗𝗞𝗡𝟮𝗔 per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Version 2.2021 𝗠𝗲𝗻 & 𝗪𝗼𝗺𝗲𝗻:Melanoma risk: Elevated at 28-67% – Recommend annual full-body skin exam, regular self-examinations, and routine sun protective behaviors. Pancreatic cancer risk: >15% – Consider MRI/MRCP and/or endoscopic …
Permanent link to this article: https://inheritedcancer.net/post51321/
ICARE Social Media Post April 2021
Reducing Hereditary Cancer Act
ICARE Social Media Post April 2021
Reducing Hereditary Cancer Act
The 𝙍𝙚𝙙𝙪𝙘𝙞𝙣𝙜 𝙃𝙚𝙧𝙚𝙙𝙞𝙩𝙖𝙧𝙮 𝘾𝙖𝙣𝙘𝙚𝙧 𝘼𝙘𝙩 is being proposed to ensure Medicare beneficiaries have access to inherited cancer genetic testing, increased screening, and risk-reducing procedures, when medically necessary & appropriate. Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Genetic testing is only …
Permanent link to this article: https://inheritedcancer.net/post43021/
ICARE Social Media Post April 2021
Komen Disparities Resource
ICARE Social Media Post April 2021
Komen Disparities Resource
Check out Susan G. Komen’s “𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗛𝗶𝘀𝘁𝗼𝗿𝘆, 𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗥𝗶𝘀𝗸” resource, which outlines disparities in breast cancer, how to understand your risk, and recommended screening and management practices. To learn more, please visit: 👉 https://www.komen.org/about-komen/our-impact/breast-cancer/health-equities-initiative/know-your-history/ 👉 https://blog.komen.org/news/black-history-month/
Permanent link to this article: https://inheritedcancer.net/post42021/
ICARE Social Media Post March 2021
STK11: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
STK11: Cancer Risks and Risk Management
Gene: STK11 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Women:Breast cancer risk: Elevated at 40-60% – Recommend annual mammogram and breast MRI starting at around age 30. Ovarian tumor risk (typically benign sex cord/Sertoli cell tumors): Elevated at 18-21% – Recommend annual pelvic exam starting at …
Permanent link to this article: https://inheritedcancer.net/post33021/
ICARE Social Media Post March 2021
MUTYH: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
MUTYH: Cancer Risks and Risk Management
Gene: MUTYH Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Men & women with two mutations in MUTYH:Colon cancer risk: High risk – Recommend colonoscopy every 1-2 years beginning at age 25-30; colectomy considered based on polyp burden and age. Duodenal cancer risk: Elevated – Consider baseline …
Permanent link to this article: https://inheritedcancer.net/post32321/
ICARE Social Media Post March 2021
APC: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
APC: Cancer Risks and Risk Management
𝗚𝗲𝗻𝗲: 𝗔𝗣𝗖 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 𝗠𝗲𝗻 & 𝗪𝗼𝗺𝗲𝗻:𝘈𝘗𝘊 mutation leading to classic form of Familial Adenomatous Polyposis (FAP):Colorectal cancer risk: >99% if untreated – Treatment is based on polyp burden and includes proctocolectomy (with subsequent endoscopic screening of the ileal pouch) or …
Permanent link to this article: https://inheritedcancer.net/post31621/
ICARE Newsletter Winter 2021
Study Suggests Low Yield of MRI Surveillance After Bilateral Mastectomy
ICARE Newsletter Winter 2021
Study Suggests Low Yield of MRI Surveillance After Bilateral Mastectomy
A study of 159 women, including BRCA1/2 carriers, who had a bilateral mastectomy with reconstruction and underwent breast MRI screening, showed few women had detection of breast cancer through MRI after their bilateral mastectomy. These results support the recommendation that BRCA1/2 carriers with or without breast cancer who have a bilateral mastectomy with reconstruction do …
Permanent link to this article: https://inheritedcancer.net/8nlw2021/
ICARE Newsletter Winter 2021
Learning You Have a Mutation in an Inherited Cancer Gene: What’s Next?
ICARE Newsletter Winter 2021
Learning You Have a Mutation in an Inherited Cancer Gene: What’s Next?
The benefits achieved through genetic testing for inherited cancer only happen by acting upon the results. This can be through guiding cancer treatment, receiving appropriate cancer risk management strategies, and sharing results with at-risk family members so they too can benefit from this information. We recently reported on results of our study, made possible through …
Permanent link to this article: https://inheritedcancer.net/6nlw2021/
ICARE Social Media Post October 2020
CDH1: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
CDH1: Cancer Risks and Risk Management
Gene: 𝘾𝘿𝙃𝟭 Cancer Risks and Management per NCCN Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021 and Gastric Version 3.2020: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 55% – Recommend annual mammogram starting at age 30; consider breast MRI with contrast starting at age 30. 𝗠𝗲𝗻 𝗮𝗻𝗱 𝗪𝗼𝗺𝗲𝗻: Stomach cancer risk: Elevated at 83% for women, and 67% …
Permanent link to this article: https://inheritedcancer.net/post103020/
ICARE Social Media Post October 2020
PTEN: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
PTEN: Cancer Risks and Risk Management
Gene: 𝙋𝙏𝙀𝙉 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 85% – Recommend annual mammogram starting at age 30-35 (or 5-10 years before the earliest known breast cancer in the family); consider breast MRI with contrast starting at age 30-35; consider …
Permanent link to this article: https://inheritedcancer.net/post102320/
ICARE Social Media Post October 2020
TP53: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
TP53: Cancer Risks and Risk Management
Gene: 𝙏𝙋𝟱𝟯 Syndrome: Li-Fraumeni Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 54% – Recommend clinical breast exam every 6-12 months starting at age 20, annual breast MRI with contrast starting at age 20, and annual mammogram starting at age 30; …
Permanent link to this article: https://inheritedcancer.net/post101620/
ICARE Social Media Post October 2020
CHEK2: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
CHEK2: Cancer Risks and Risk Management
Gene: 𝘾𝙃𝙀𝙆2 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 & Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast Cancer Risk: Elevated at 28-44% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs with contrast starting at age 40. 𝗠𝗲𝗻 𝗮𝗻𝗱 𝗪𝗼𝗺𝗲𝗻: Colorectal Cancer Risk: Elevated …
Permanent link to this article: https://inheritedcancer.net/post100920/
Permanent link to this article: https://inheritedcancer.net/video100820/
ICARE Social Media Post October 2020
ATM: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
ATM: Cancer Risks and Risk Management
Gene: 𝘼𝙏𝙈 Cancer Risks and Management (per NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2021) 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 30% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs starting at age 40. Ovarian cancer risk: Possibly increased, not well established – Manage based on family history. …
Permanent link to this article: https://inheritedcancer.net/post100220/
ICARE Social Media Post August 2020
MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction
ICARE Social Media Post August 2020
MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction
A study of 159 women, including BRCA carriers, who had bilateral mastectomy with reconstruction, underwent breast MRI screening. The results showed few women had detection of breast cancer through MRI, after their bilateral mastectomy. These results support the recommendation against screening MRI in women who have had bilateral mastectomy with reconstruction due to a diagnosis …
Permanent link to this article: https://inheritedcancer.net/post81820/
ICARE Newsletter Summer 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines
ICARE Newsletter Summer 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines (Version 1.2020, posted July 21, 2020) For individuals with Lynch Syndrome: Cancer risks were updated based on information from recent studies: Main updates included cancer risks in PMS2 (endometrial, ovarian, and prostate cancer), MSH2 and EPCAM (prostate and brain cancer), and MSH6 (prostate …
Permanent link to this article: https://inheritedcancer.net/1nls2020/
ICARE Social Media Post August 2020
Inherited Prostate Cancer Risk
ICARE Social Media Post August 2020
Inherited Prostate Cancer Risk
Over 600,000 men age 40 and older who were part of a family with at least three consecutive generations affected with prostate cancer were studied from the Utah Population Database. Findings from this study showed that: 36,000 had prostate cancer (5.9%) 2,500 had early-onset disease (7%) 4,000 had lethal disease (11.1%) 15,000 had clinically significant …
Permanent link to this article: https://inheritedcancer.net/post81420/
ICARE Social Media Post August 2020
CDC Resource for Free Breast Cancer Screening
ICARE Social Media Post August 2020
CDC Resource for Free Breast Cancer Screening
We are here to help! Our followers asked us to provide information about screening resources for women with hereditary breast cancer. We would like to make folks aware about a CDC program that provides free breast cancer screening for women who are uninsured and underinsured. Check out more information at: https://www.cdc.gov/cancer/nbccedp/
Permanent link to this article: https://inheritedcancer.net/post81120/
ICARE Publication July 2020
Update on multi-gene panel testing and communication of genetic test results
ICARE Publication July 2020
Update on multi-gene panel testing and communication of genetic test results
Abstract With technological advances, multi-gene panel testing has become increasingly used to identify patients at risk for hereditary breast cancer (HBC). There are currently evidence-based interventions and breast cancer screening strategies that exist for cancer prevention and early detection among patients with HBC. Moreover, in addition to the personal impact of identifying HBC, this information …
Permanent link to this article: https://inheritedcancer.net/pub70820/
ICARE Publication May 2020
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers
ICARE Publication May 2020
Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers
Abstract Purpose: Identification of inherited breast cancer may guide cancer risk management. We sought to compare risk management practices across women with inherited breast cancer genes. Methods: Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about cancer risk management. Comparisons were made across genes. Results: The 235 participants with P/LP variants …
Permanent link to this article: https://inheritedcancer.net/pub52220/
ICARE Social Media Post May 2020
MRI May Detect Breast Cancer Earlier than Mammograms
ICARE Social Media Post May 2020
MRI May Detect Breast Cancer Earlier than Mammograms
The National Comprehensive Cancer Network (NCCN) currently recommends an annual breast MRI and an annual mammography for high-risk women (lifetime breast cancer risk at or above 20%). Among women at high risk for breast cancer, MRI detected breast cancer at an earlier stage than mammograms. Women with BRCA1/2 and TP53 were NOT included in this …
Permanent link to this article: https://inheritedcancer.net/post51520/
ICARE Social Media Post May 2020
New Blood Test May Find Ovarian Cancer Early
ICARE Social Media Post May 2020
New Blood Test May Find Ovarian Cancer Early
A study of 80 women identified 4 proteins in blood that may help to detect ovarian cancer early. Further research is still needed with larger groups of women to determine if this new blood test would be a reliable test to find ovarian cancer early. Check out the full article at https://www.nature.com/articles/s41416-019-0544-0
Permanent link to this article: https://inheritedcancer.net/post50120/
ICARE Social Media Post April 2020
PALB2: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
PALB2: Cancer Risks and Risk Management
Gene: PALB2 Cancer Risks and Management (per NCCN version 1.2020): Women: Breast cancer risk: Elevated at 53% – Recommend annual breast MRI with contrast starting at age 30, and annual mammogram with consideration of tomosynthesis starting at age 30; Consider risk-reducing mastectomy. Ovarian cancer risk: Elevated at 5% – Manage based on family history. Men …
Permanent link to this article: https://inheritedcancer.net/post42820/
ICARE Social Media Post April 2020
BRCA2: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
BRCA2: Cancer Risks and Risk Management
Gene: BRCA2 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …
Permanent link to this article: https://inheritedcancer.net/post42120/
ICARE Social Media Post April 2020
BRCA1: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
BRCA1: Cancer Risks and Risk Management
Gene: BRCA1 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …
Permanent link to this article: https://inheritedcancer.net/post41420/
ICARE Social Media Post April 2020
EPCAM: Cancer Risks and Risk Management
ICARE Social Media Post April 2020
EPCAM: Cancer Risks and Risk Management
Gene: EPCAM Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …
Permanent link to this article: https://inheritedcancer.net/post4120/
ICARE Social Media Post March 2020
PMS2: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
PMS2: Cancer Risks and Risk Management
Gene: PMS2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 0%-15% – Consider risk-reducing hysterectomy. Men and Women: Colorectal cancer risk: Elevated at 12%-20% – Recommend colonoscopy every 1-2 years starting at age 20-25 Gastric cancer risk: Not well established – Consider upper endoscopy every 3-5 years beginning at …
Permanent link to this article: https://inheritedcancer.net/post32420/
ICARE Social Media Post March 2020
Study Based on ICARE Participants with ATM and CHEK2 Mutations
ICARE Social Media Post March 2020
Study Based on ICARE Participants with ATM and CHEK2 Mutations
Women with ATM and CHEK2 mutations have a lifetime breast cancer risk greater than 20%, which is the threshold at which screening through a breast MRI is recommended. A recently published study based on ICARE participants with ATM and CHEK2 mutations suggested that most female family members of ATM and CHEK2 mutation carriers do not …
Permanent link to this article: https://inheritedcancer.net/post32020/
ICARE Social Media Post March 2020
MSH6: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
MSH6: Cancer Risks and Risk Management
Gene: MSH6 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: 17%-46% – Consider risk-reducing hysterectomy. Ovarian cancer risk: 1%-11% – Evidence is insufficient to make specific recommendations. Men and Women: Colorectal cancer risk: 15%-44% – Recommend colonoscopy every 1-2 years starting at age 20-25. Gastric cancer risk: 0%-5% – Consider upper …
Permanent link to this article: https://inheritedcancer.net/post31720/
ICARE Social Media Post March 2020
Polygenic Risk Score and Colon Cancer Risk
ICARE Social Media Post March 2020
Polygenic Risk Score and Colon Cancer Risk
A Polygenic Risk Score (PRS) is calculated using genetic differences throughout someone’s DNA, in combination with clinical and family history of cancer. This score, alongside environmental and lifestyle risk factors, may help to identify people who might benefit from screening at an earlier age. Important facts about PRS: – It does NOT look for changes …
Permanent link to this article: https://inheritedcancer.net/post31320/
ICARE Social Media Post March 2020
MSH2: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
MSH2: Cancer Risks and Risk Management
Gene: MSH2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …
Permanent link to this article: https://inheritedcancer.net/post31020/
ICARE Social Media Post March 2020
MLH1: Cancer Risks and Risk Management
ICARE Social Media Post March 2020
MLH1: Cancer Risks and Risk Management
Gene: MLH1 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 43%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 5%-20% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Breast cancer risk: Elevated at 12%-17% – Manage same as general population. Men and Women: Colorectal cancer …
Permanent link to this article: https://inheritedcancer.net/post3320/
ICARE Newsletter Winter 2020
PALB2 Mutations & Cancer Risk
ICARE Newsletter Winter 2020
PALB2 Mutations & Cancer Risk
A newly published study of 524 families with pathogenic PALB2 mutations from around the world, including almost 50 ICARE participants, represents the largest, most comprehensive effort to evaluate cancer risks.1 Results showed increased risks for female breast cancer (53%), ovarian cancer (5%), pancreatic cancer (2-3%), and male breast cancer (1%). Findings did not suggest higher …
Permanent link to this article: https://inheritedcancer.net/6nlw2020/
ICARE Newsletter Winter 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
ICARE Newsletter Winter 2020
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
There were significant updates and restructuring of the guidelines, with some highlights included below: Substantial reorganization of the guidelines as follows: Now organized by organ site, rather than primarily by certain high penetrance genes Focused efforts to simplify genetic testing criteria Only one flow diagram included, to outline the ‘genetic testing process’ Following scenarios now …
Permanent link to this article: https://inheritedcancer.net/1nlw2020/
ICARE Newsletter Winter 2020
Updated Pancreatic Cancer Screening Guidelines through CAPS Consortium
ICARE Newsletter Winter 2020
Updated Pancreatic Cancer Screening Guidelines through CAPS Consortium
The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated recommendations about pancreatic cancer screening through MRI/magnetic retrograde cholangiopancreatography (MRCP) and/or an endoscopic ultrasound (EUS).1 Specifically, these guidelines now recommend that individuals with a CDKN2A or STK11 mutation begin screening at age 40. Screening for individuals with a BRCA1/2, ATM, PALB2, MLH1, or …
Permanent link to this article: https://inheritedcancer.net/4nlw2020/
ICARE Social Media Post February 2020
Differences in Pancreatic Cancer Screening Recommendations from the National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium
ICARE Social Media Post February 2020
Differences in Pancreatic Cancer Screening Recommendations from the National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium
The National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium recently updated pancreatic cancer screening recommendations. However, there are some differences between these recommendations. Specifically, screening with annual MRI/magnetic retrograde cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS) is recommended as follows for NCCN versus CAPS: STK11 regardless of family history: …
Permanent link to this article: https://inheritedcancer.net/post2620/
ICARE Social Media Post February 2020
Updated Pancreatic Cancer Screening Guidelines through the International Cancer of the Pancreas Screening (CAPS) Consortium
ICARE Social Media Post February 2020
Updated Pancreatic Cancer Screening Guidelines through the International Cancer of the Pancreas Screening (CAPS) Consortium
The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated pancreatic cancer screening recommendations. The recommendations include: Screening with MRI/magnetic retrograde cholangiopancreaography (MRCP) and/or endoscopic ultrasound (EUS) The screening was recommended for the following individuals: CDKN2A and STK11 mutation carriers starting at age 40 BRCA1/2, ATM, PALB2, MLH1, and MSH2 mutation carriers (if …
Permanent link to this article: https://inheritedcancer.net/post2420/
ICARE Publication January 2020
Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers
ICARE Publication January 2020
Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers
Abstract Background: With the increasing use of multigene panel tests, pathogenic and likely pathogenic (P/LP) variants are identified more frequently in the moderate-penetrance breast cancer genes ATM and CHEK2. Lifetime breast cancer risk among women with P/LP variants in these genes generally exceeds 20%, meeting the threshold at which high-risk breast cancer screening through breast magnetic …
Permanent link to this article: https://inheritedcancer.net/pub12220/
ICARE Social Media Post January 2020
Ovarian Cancer Screening in BRCA1 Carriers
ICARE Social Media Post January 2020
Ovarian Cancer Screening in BRCA1 Carriers
A new study of Polish BRCA1 carriers showed that screening through transvaginal ultrasound was not effective or reliable in detecting ovarian cancer early. Consequently, preventive oophorectomy remains the only proven method to lower ovarian cancer risks and increase survival. Check out the article at: https://www.ncbi.nlm.nih.gov/pubmed/31500890. Check out the NCCN ovarian cancer screening recommendations for BRCA1 …
Permanent link to this article: https://inheritedcancer.net/post11720/
ICARE Social Media Post January 2020
Women with BRCA1/2: Risk-reducing Mastectomy versus Screening
ICARE Social Media Post January 2020
Women with BRCA1/2: Risk-reducing Mastectomy versus Screening
In a study of 5000 healthy female BRCA1/2 carriers (without a breast cancer diagnosis): BRCA1 carriers: after an average of over 10 years follow-up, survival was higher in those who had bilateral mastectomy (99.7%) compared to those who had breast screening through mammograms and breast MRIs (93%). BRCA2 carriers: no significant differences were seen between …
Permanent link to this article: https://inheritedcancer.net/post11020/
ICARE Social Media Post December 2019
PALB2 Mutations and Cancer Risk
ICARE Social Media Post December 2019
PALB2 Mutations and Cancer Risk
A new published study of 524 families with PALB2 mutations, including our very own ICARE participants, from around the world showed increased risks of female breast, ovarian, pancreatic, and male breast cancer. The level of risk for female breast cancer is enough to recommend cancer risk management. Cancer risk management includes screening or risk-reducing surgery. …
Permanent link to this article: https://inheritedcancer.net/post121619/
ICARE Featured Video December 2019
NCCN Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines
ICARE Featured Video December 2019
NCCN Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines
Below you may watch a featured video from the December 2019 Genetics Case Conference, which outlined updates to the National Comprehensive Cancer Network (NCCN) guidelines.
Permanent link to this article: https://inheritedcancer.net/video121219/
ICARE Social Media Post December 2019
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines (V1.2020)
ICARE Social Media Post December 2019
Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines (V1.2020)
We are excited to share the latest version of the NCCN Genetic/Familial Breast, Ovarian and Pancreatic Guidelines (V1.2020), which were just updated. Some of the changes made include: PALB2 was added as a high penetrance gene (similar to BRCA1, BRCA2, CDH1, PTEN and TP53) It is appropriate to consider risk reducing mastectomy for cancer risk management …
Permanent link to this article: https://inheritedcancer.net/post12419/
ICARE Publication April 2019
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
ICARE Publication April 2019
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
Abstract Background: Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer. In the current study, we report on uptake of cancer screening and risk-reduction options in a cohort of BRCA mutation carriers from ten countries over two time periods (1995 to 2008 and 2009 to 2017). Methods: Eligible subjects were identified …
Permanent link to this article: https://inheritedcancer.net/pub41119/
ICARE Newsletter Winter 2019
Advances in Biomarkers to Detect Pancreatic Cancer Early
ICARE Newsletter Winter 2019
Advances in Biomarkers to Detect Pancreatic Cancer Early
Early detection of pancreatic cancer is tremendously important, given that most patients who develop the disease are diagnosed at a later stage of the disease when it is usually incurable. Although screening through imaging studies has been proposed (i.e., magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound),1 data to support this type of screening as an …
Permanent link to this article: https://inheritedcancer.net/12nlw2019/
ICARE Newsletter Winter 2018
Getting Closer to Detecting Cancers Early Through a Blood Test?
ICARE Newsletter Winter 2018
Getting Closer to Detecting Cancers Early Through a Blood Test?
A recent study reported on a single blood test, named “CancerSEEK”, which can screen for 8 common types of cancer (ovarian, liver, stomach, pancreas, esophagus, colorectal, lung, and breast) and may help to identify the location at which the cancer started. This test evaluated the blood from over 1000 patients with Stage 1 to 3 …
Permanent link to this article: https://inheritedcancer.net/2nlw2018/
ICARE Newsletter Winter 2018
Advances in Cancer Screening Among Li-Fraumeni Syndrome Patients
ICARE Newsletter Winter 2018
Advances in Cancer Screening Among Li-Fraumeni Syndrome Patients
Several research groups from around the world that have conducted cancer screening among patients with Li-Fraumeni syndrome and a germline TP53 mutation have recently reported on their observations. Specifically, the National Cancer Institute group demonstrated that screening inclusive of rapid total body MRI detected cancers at an early stage,1 similar to findings published through other …
Permanent link to this article: https://inheritedcancer.net/5nlw2018/
ICARE Newsletter Summer 2017
Ask the Expert
ICARE Newsletter Summer 2017
Ask the Expert
The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at the Women’s College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Q. In women with a BRCA mutation and …
Permanent link to this article: https://inheritedcancer.net/6nls2017/
ICARE Newsletter Summer 2017
What Are the Benefits of Adding a Mammogram to MRI for Breast Cancer Screening Among Women with BRCA Mutations?
ICARE Newsletter Summer 2017
What Are the Benefits of Adding a Mammogram to MRI for Breast Cancer Screening Among Women with BRCA Mutations?
Recently, researchers evaluated the benefit of adding a mammogram to MRI for breast cancer screening among ~2000 women with a BRCA1 or BRCA2 mutation. Results indicated that the addition of mammography to MRI did not substantially raise the chance of detecting breast cancer in the overall group. However, one-third of breast cancer cases diagnosed among …
Permanent link to this article: https://inheritedcancer.net/7nls2017/
ICARE Newsletter Winter 2017
New Study Suggesting BRCA1/2 and ATM Are Associated with Aggressive Prostate Cancer
ICARE Newsletter Winter 2017
New Study Suggesting BRCA1/2 and ATM Are Associated with Aggressive Prostate Cancer
Among 799 patients with prostate cancer, the rate of BRCA1/2 mutations was much higher among those who passed away of prostate cancer (6.07%) compared to those with low risk disease (1.44%).1 Among the group that died of prostate cancer, those with BRCA1/2 or ATM mutations passed away at an earlier age and had a shorter …
Permanent link to this article: https://inheritedcancer.net/3nlw2017/
ICARE Newsletter Winter 2017
NCCN Guidelines Version 1.2017: Genetic/Familial High-Risk Assessment: Breast and Ovarian
ICARE Newsletter Winter 2017
NCCN Guidelines Version 1.2017: Genetic/Familial High-Risk Assessment: Breast and Ovarian
Additional guidance pertaining to cancer risk management was provided in the most recent version of the NCCN Guidelines for inherited breast and ovarian cancer. These guidelines now include an expanded table outlining cancer risks and management for each gene, taking into account the age at initiation of each risk management modality as well as footnotes …
Permanent link to this article: https://inheritedcancer.net/1nlw2017/
ICARE Newsletter Winter 2017
The Potential Promise of Immunotherapy Targeted to Those with Bi-Allelic Mutations in Lynch Syndrome Genes
ICARE Newsletter Winter 2017
The Potential Promise of Immunotherapy Targeted to Those with Bi-Allelic Mutations in Lynch Syndrome Genes
People with Lynch Syndrome have a non-working Lynch gene (“mutation”), while the other copy of that gene is normal (recognizing that all of these genes come in pairs, with one member of the pair coming from each parent). Over the last few years, there has been an increased realization that some individuals have a mutation …
Permanent link to this article: https://inheritedcancer.net/2nlw2017/
ICARE Newsletter Summer 2016
Surveillance Among Individuals with Li-Fraumeni Syndrome (LFS): An 11 Year Follow-Up Study
ICARE Newsletter Summer 2016
Surveillance Among Individuals with Li-Fraumeni Syndrome (LFS): An 11 Year Follow-Up Study
Results from the original screening protocol for LFS1 were recently updated following collection of 11 years of follow-up data.2 Through this study, 89 patients with LFS were given the option of a clinical surveillance protocol consisting of a physical examination as well as frequent biochemical and imaging studies. Forty asymptomatic tumors were detected in 32% …
Permanent link to this article: https://inheritedcancer.net/4nls2016/
ICARE Newsletter Summer 2016
An Approach to Making Risk Management Recommendations for Newer Inherited Cancer Genes
ICARE Newsletter Summer 2016
An Approach to Making Risk Management Recommendations for Newer Inherited Cancer Genes
A recent article sought to develop an approach to cancer risk management among individuals with mutations in newer inherited cancer genes, many of which result in a moderate (rather than ‘high’) cancer risk. Overall, the investigators suggest a framework that takes the age-specific, lifetime, and absolute cancer risks into account for inherited cancer genes where …
Permanent link to this article: https://inheritedcancer.net/3nls2016/
ICARE Newsletter Winter 2016
More Information About the Inherited Component of Pancreatic Cancer
ICARE Newsletter Winter 2016
More Information About the Inherited Component of Pancreatic Cancer
Although pancreatic cancer is one of the cancer types seen among individuals with mutations in inherited cancer genes (including BRCA2 and BRCA1), the proportion of individuals with pancreatic cancer who have an inherited cause has remained uncertain. To further clarify the role of BRCA1 and BRCA2 (BRCA), over 300 patients with pancreatic cancer were tested …
Permanent link to this article: https://inheritedcancer.net/7nlw2016/
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines For breast cancer screening in BRCA carriers, yearly MRI is recommended starting at age 25; mammograms may be considered in instances where MRI is unavailable or individualized based on earliest age of onset in the family. From age 30-75, annual mammogram and breast MRI is recommended. Above age …
Permanent link to this article: https://inheritedcancer.net/5nlw2015/
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
ICARE Newsletter Winter 2015
Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update
Genetic/Familial High-Risk Assessment: Colorectal Guidelines Recommendation that tumors from newly diagnosed colorectal cancer patients be screened for Lynch syndrome (called “Universal Tumor Screening”). A new algorithm was created for Routine Tumor Testing Criteria for Lynch Syndrome Surveillance/Management recommendations were refined by gene for the various Lynch Syndrome genes. Management recommendations were refined for other inherited …
Permanent link to this article: https://inheritedcancer.net/6nlw2015/
ICARE Newsletter Summer 2014
Early Results to Suggest That PSA Screening May Help to Detect Prostate Cancer Early in Men with BRCA Mutations
ICARE Newsletter Summer 2014
Early Results to Suggest That PSA Screening May Help to Detect Prostate Cancer Early in Men with BRCA Mutations
Over the last few years, there have been a number of studies to suggest that men with BRCA mutations, particularly BRCA2, have a higher risk of developing aggressive prostate cancer. It remains uncertain whether these men might benefit from screening through the prostate-specific antigen (PSA) test. Within the last few years, PSA screening guidelines in …
Permanent link to this article: https://inheritedcancer.net/1nls2014/
ICARE Newsletter Winter 2014
Recent Evidence to Suggest That Individuals with Germline Mutations in the PTEN gene (Which Leads to Cowden Syndrome) May Have Higher Renal Cancer Risks
ICARE Newsletter Winter 2014
Recent Evidence to Suggest That Individuals with Germline Mutations in the PTEN gene (Which Leads to Cowden Syndrome) May Have Higher Renal Cancer Risks
Cowden Syndrome is an inherited condition that leads to higher risks for breast and thyroid cancer, and possibly other cancers.1 There have been a few recent studies that suggest that this condition also puts individuals at a higher risk for kidney cancer. Specifically, Tan et al2 reported a lifetime risk of 30.6% (95% CI: 17.8-49.4) …
Permanent link to this article: https://inheritedcancer.net/3nlw2014/
ICARE Newsletter Winter 2014
Ask the Expert
ICARE Newsletter Winter 2014
Ask the Expert
The following question was addressed by Dr. Laronga who is a breast surgeon based at the Moffitt Cancer Center: Q. What are the risks of breast cancer after ovarian cancer in BRCA carriers? What risk management options are recommended? A. BRCA carriers remain at a higher risk of breast cancer, even after having ovarian cancer; …
Permanent link to this article: https://inheritedcancer.net/4nlw2014/
ICARE Newsletter Summer 2013
Ask the Expert
ICARE Newsletter Summer 2013
Ask the Expert
The following question was addressed by Dr. Pal, who is a Clinical Geneticist based at the Moffitt Cancer Center: Q. Does exposure to radiation increase breast cancer risk in BRCA mutation carriers? A. A number of studies have been conducted to evaluate whether BRCA mutation carriers may be more prone to radiation-induced breast cancer than …
Permanent link to this article: https://inheritedcancer.net/6nls2013/
ICARE Newsletter Summer 2012
Emerging Cancer Panels for Testing Patients for Inherited Cancer Predisposition
ICARE Newsletter Summer 2012
Emerging Cancer Panels for Testing Patients for Inherited Cancer Predisposition
Genetic testing for inherited cancer predisposition is typically performed by testing for one condition at a time. However, with the tremendous advances in genetic testing technologies over the last few years, the cost of testing has plummeted. To put this into perspective, the first human genome cost 2-3 billion dollars to sequence and took over …
Permanent link to this article: https://inheritedcancer.net/1nls2012/
ICARE Newsletter Summer 2012
Prostate Cancer Screening Recommendations for Men with BRCA Mutations
ICARE Newsletter Summer 2012
Prostate Cancer Screening Recommendations for Men with BRCA Mutations
Over the last few years, there have been several studies that suggest that men with BRCA mutations are at a higher risk for developing and dying from aggressive prostate cancer. It is possible that PSA testing may be of benefit in men with BRCA mutations. However, until the utility of PSA is determined in these …
Permanent link to this article: https://inheritedcancer.net/2nls2012/
Follow us to stay informed
Click below to read recent updates on inherited cancers
Click below to read inspiring stories from our ICARE participants
